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Human immunodeficiency virus type 1 (HIV-1) strains isolated from the central nervous system (CNS) may 
represent a subgroup that displays a host cell tropism different from those isolated from peripheral blood and 
lymph nodes. One CNS-derived isolate, HIV-lS,,,,,, which can be propagated efficiently in primary 
macrophage culture but not in any T-cell lines, was molecularly cloned and characterized. Recombinant viruses 
between HIV-ls,l,,A and the peripheral blood isolate HIV-I,,, were generated in order to map the viral 
gene(s) responsible for the macrophage tropism. The env gene sequences of the two isolates are about 91.1% 
homologous, with variations scattered mainly in the hypervariable regions of gp120. Recombinant viruses that 
have acquired the HIV-l,,l,,A env gene display HIV-ls,l,,A tropism for macrophages. Furthermore, the 
gp120 variable domains, V,, V,, V,, and V,, the CD4-binding domain, and the gp41 fusion domain are not 
directly involved in determining macrophage tropism. 
Acquired immunodeficiency syndrome (AIDS) is a disease 
caused by the human immunodeficiency virus (HIV). In- 
fected individuals often develop neurological disorders in 
addition to severe immune dysfunctions (23, 29). These 
diseases include encephalopathy, dementia, and vacuolar 
degeneration of the spinal cord (8). In many cases, infectious 
HIV has been isolated from brain tissues or cerebrospinal 
fluid of patients (15, 22), and the types of brain cells that 
have been shown to be infected by HIV include macro- 
phages (16, 34), endothelial cells, and glial cells (20, 26, 34). 
Furthermore, HIV strains recovered from brain tissue can 
be distinguished from peripheral blood isolates by their 
ability to infect different cell types and in their sensitivity to 
serum neutralization (4, 6). These findings suggest that 
brain-derived isolates represent a distinct subgroup of HIV 
with differential properties, particularly cellular tropism. 
An HIV type 1 isolate (HIV-1sF128A) recovered at autopsy 
from the spinal cord of an HIV-1-infected individual with 
dementia displays biologic and serologic properties charac- 
teristic of brain-derived isolates (6). HIV-1s,128A does not 
grow in any cultured T-cell lines, such as HUT 78, CEM, or 
Jurkat, or in the monocytic cell line U937 but can be 
propagated efficiently in peripheral blood mononuclear cells 
(PBMC) or primary macrophages. The viral gene(s) respon- 
sible for these distinct biological properties and host-range 
specificities of HIV-1sF12,A has not been defined. Thus, a 
detailed molecular characterization of this isolate should 
generate valuable information concerning the regulation of 
viral replication and pathogenesis. 
MATERIALS AND METHODS 
Cell cultures. Phytohemagglutinin (3 kg1ml)-stimulated 
PBMC from HIV-1-seronegative individuals were prepared 
on Ficoll-Hypaque gradients as described elsewhere (10) and 
propagated in RPMI 1640 medium containing 10% heat- 
inactivated (56°C for 30 min) fetal calf serum, glutamine (2 
* Corresponding author. 
C 
mM), penicillin (100 Ulml), streptomycin (100 kglrnl), 
and 5% interleukin-2 (Pharmacia EN1 Diagnostic, Inc., 
Silver Spring, Md.). Purified CD4+ cells were prepared by 
the panning procedure with Leu 3a monoclonal antibodies 
(Becton Dickinson, Mountain View, Calif.) as described 
previously (35) and maintained in the same medium. The 
HUT 78 cell line (obtained from the American Type Culture 
Collection, Rockville, Md.) was maintained in the same 
medium without interleukin-2. Primary monocytes were 
obtained from Ficoll-Hypaque gradient-purified PBMC by 
the plastic adherent technique (6, 13). Adherent cells were 
cultured for 10 to 12 days in RPMI 1640 medium supple- 
mented with 10% fetal calf serum, 5% heat-inactivated 
human serum, and 1% antibiotics to allow differentiation into 
macrophages. Human rhabdomyosarcoma (RD-4) cells were 
obtained from the American Type Culture Collection and 
maintained as monolayer cultures in Dulbecco's modified 
Eagle medium supplemented with 10% fetal calf serum and 
antibiotics. 
Virus. HIV-I,,,, our prototype peripheral blood isolate 
(formerly called AIDS-associated retrovirus ARV-2), was 
recovered by cocultivation of mitogen-stimulated PBMC 
from seronegative donors with PBMC from a patient with 
oral candidiasis (21). HIV-Is,, had been molecularly cloned 
and sequenced (25, 33): the molecular clone is biologically 
active (19). HIV-1sF128A was obtained by cocultivation of 
PBMC from seronegative donors with spinal cord tissue 
obtained at autopsy from an HIV-1-positive patient with 
dementia (6, 20). Both isolates were grown to high titers in 
PBMC, reaching levels of reverse transcriptase (RT) activity 
of >lo6 cpmlml. Culture fluids were then filtered through 
0.45-km-pore-size filters and frozen at -70°C in 1-ml ali- 
quots. 
HIV infection and transfection. Human PBMC, CD4+ 
cells, HUT 78 cells. and primary macrophages were infected 
with HIV-1 inocula of equal RT level (106cpm/ml) as de- 
scribed previously (6, 10). Transfection of HIV-1 DNA into 
human PBMC and the RD-4 cell line by the DEAE-dextran 
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TABLE 1. Comparison of host range properties of HIV-lsF2,, 
and HIV-1s,12,A 
Replication" in: 
Strain or clone Initial source 
PBMC HUT 78 cells Mb  
PBMC 1,150.0 
Spinal cord 797.0 
tissue 
" Replication of recombinant viruses was determined as described in 
Materials and Methods. Virus replication was measured by levels of RT 
activity (10' cpmlml) detected in culture supernatants 3- to 4-day intervals. 
For replication in PBMC. RT activity at 10 days postinfection is shown. For 
replication in HUT 78 cells and primary macrophages (M6). RT values at 15 
days postinfection are shown. All data shown are representative of three 
independent experiments. 
mc, Molecular clone. 
Replication of RHIV-2 and RHIV-5 in PBMC reached RT titers of >5 x 
10' c p d m l  at 12 days postinfection. 
and calcium phosphate precipitation methods, respectively, 
was performed as described previously (19). 
Cloning of HIV-l,,,,, provirus. In order to clone the 
proviral genome, PBMC from a seronegative donor were 
infected with HIV-1,F128A. At 10 days postinfection, about 
10' cells from infected cultures were collected, washed, and 
disrupted, and the viral DNA was isolated by the Hirt 
extraction procedure (14). The Hirt method-extracted DNA 
was then digested with Sac1 and fractionated on a 10 to 40% 
sucrose gradient, and each fraction was then tested for 
hybridization with an HIV-I,,, probe. Positive fractions 
were then isolated and cloned Into a SacI-cut lambda Wes 
vector (18). A recombinant library of about 5 x lo5 phages 
was then screened with the HIV-I,,, probe (25) for positive 
clones by standard techniques (32). 
Nucleotide sequence accession number. The sequence data 
presented in this article have been submitted to the GenBank 
and EMBL data bases under the accession number M38673. 
RESULTS 
Biologic properties of HIV-l,,,,,,. In contrast to the 
peripheral blood HIV-1 isolate, HIV-I,,,, the brain-derived 
HIV-1,F,28A strain does not productively infect the HUT 78 
T-cell line but replicates efficiently in primary macrophages 
(Table 1). High levels of RT activity were detected in 
supernatants of infected macrophages for over 35 days in 
culture. Furthermore, HIV-1,F128, is not highly cytopathic 
for CD4+ lymphocytes and does not down-modulate the 
CD4 receptor molecule upon infection of these cells (6). 
These biologic features of HIV-1,F128A are characteristic of 
brain-derived HIV-1 isolates (6). 
Characterization of the HIV-1,,l,8A clone. Several positive 
clones were identified from the recombinant library, and one 
of them, which encompasses a 9-kb viral insert, was then 
characterized further. This clone contains the entire viral 
genome except for part of the long terminal repeat (LTR). 
Thus, this clone is not biologically active. Restriction endo- 
nuclease digestion mapping of the HIV-1,F128A was per- 
formed and compared with mapping of HIV-I,,,. The two 
viruses share many restriction enzyme sites. Both HIV- 
- --- 
- -  - - 
- 
-  - 
HIV-I  SF^ k '  I 
- 
LTR - POL -=- 
GAG ENV LTR 
BssH II Sst I 
RHIV-I B 
RHIV-2 
Slu l 
RHIV-3 
RHIV.5 -* 
Mst II tfst II 
RHIV-6 I - 
FIG. 1. Schematic representation of the genomes of HIV-I,,,, 
HIV-lsFlZuA, and their recombinant clones. (A) Restriction enzyme 
map of HIV-lsFl,,A in comparison with the map of HIV-l,,,. The 
restriction map of HIV-I,,, has been determined previously (33). 
(B) Structures of HIV-1s,,/HIV-1s,12u recombinant clones. These 
clones were constructed by using specific restriction enzymes as 
described in the text. 
1sF128A and HIV-I,,, have common unique EcoRI, BssHII, 
StuI, and XhoI sites (Fig. 1A). The coding sequences across 
the BssHII, StuI, and XhoI sites were all conserved. These 
sites were then subsequently used for generation of recom- 
binant clones between HIV-I,,, and HIV-1,F128A (Fig. 1B). 
The minor restriction enzyme site differences between the 
two strains included two extra HindIII sites in the env gene 
of HIV-l,Fl,,A that were not present in HIV-I,,,. Con- 
versely, HindIII sites in the gag gene and 5' end of the env 
gene of HIV-I,,, were not found in HIV-1,F128A. Differ- 
ences were also observed with other enzyme sites such as 
BglII and PvuII (data not shown). However, no substantial 
changes in genomic organization between HIV-1,F128, and 
HIV-I,,, were found. 
Sequence analysis of HIV-I,,,,,, env and nef genes. Since 
the 3' half of the viral genome encompassing the env and nef 
genes could be the critical region that affects viral growth 
and cellular tropism (5, 11, 24, 36). we determined the 
genomic sequence of this region. The nucleotides and the 
predicted amino acid sequences of the env and nef genes 
were then compared with those of HIV-l,,,. The differences 
in sequence between the two isolates are summarized in 
Table 2. The env genes show an overall homology in 
nucleotide sequence of 91.1% and an amino acid homology 
of 85.1%. As expected, the variations are much greater in 
gp120 than in gp41. Most of the changes in gp120 reside in 
the hypervariable V,, V,, and V, domains, as well as in the 
CD4-binding domain (amino acids 411 to 464) (Fig. 2). 
Substitutions, deletions, and insertions were also observed, 
especially in the beginning of the CD4-binding domain, 
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TABLE 2. Sequence homology between HIV-lSF2,, 
and HIV-1sF128A 
Gene or 
gene 
segment 
% Homology 
Nucleotides Amino acids 
Total env 
gp120 
gp41 
n e f  
where there is a stretch of nine amino acid insertions. In 
addition, changes in the putative gp41 fusion domain were 
noted (amino acids 519 to 546). Three independent env gene 
clones of HIV-1sF128A were sequenced, and all of these 
changes in the variable, CD4-binding, and fusion domains 
were conserved among all three clones (data not shown). 
Comparison of the nef sequences revealed a 96% nucleo- 
tide homology and a 90.4% amino acid homology between 
the two isolates. However, a stretch of 45 duplicated amino 
acids is found in the HIV-lSFl2,, nef sequence at the 
beginning of the LTR in the U, region (Fig. 3). This 
duplication makes the HIV-lSFl2,, nef protein 251 amino 
acids long, whereas the HIV-I,,, nef protein is only 210 
amino acids long. This nef duplication could have occurred 
during viral replication or during cloning. However, nef 
duplication has also been observed in another brain isolate of 
HIV-1 (2). The biological significance of this duplication is 
currently not known. 
Generation of recombinant clones between HIV-l,,,,,, and 
HIV-I,,,. In order to locate the gene(s) that is responsible 
for the specific cellular tropism for HIV-l,,,,,,, a series of 
recombinants were generated between HIV-1,F128A and 
HIV-I,,, (Fig. 1B). These clones were made by using the 
BssHII, StuI, XhoI, and MstII restriction enzyme sites. The 
RHIV-1 clone expresses all of the HIV-l,,,,,, genes by 
using the HIV-lSF2 LTR. This clone was made by exchang- 
ing the complete genomes, except the LTRs, of the two 
viruses. A second recombinant clone, RHIV-2, was gener- 
ated by replacing the BssHII-XhoI fragment of HIV-Is,, 
with that of HIV-l,,,,,,. This fragment extends from the 
end of the 5' LTR to the 5' region of nef and contains 
complete gag, pol, vif,  env, tat, vpr, vpu, and rev genes of 
HIV-1,F128A. The resulting clone expresses all HIV-1sF128A 
genes except the nef gene which encodes a hybrid protein 
with the first 34 amino acids from HIV-1,F128A and the rest 
of the protein from HIV-I,,,. A third clone, RHIV-3, was 
generated by replacing a 2.8-kb SruI-SstI fragment of HIV- 
* * * * * * * * * * 
SF128A env 1 MKVKETRKNCRHWWKWGIMLLGMLLICSATEKLWVTIWGWVWKEATTTLFCASDAKASDTE~ATHACVPTDPNPQEWLENVTENFNMWKNNMVEQMHED 
SF2 env 1 ---- g--r-yq--lr--t------m------------v--------------------r-y------------------------- g----------------- 9-- 
* * * * "1 * * * * "2 * * 
107 IISLWDQSLKPCVKLTPLCVTLNCTDNLDLRNDTNTNDTNATSSSLRGETGEIKNCSFNITTSIRDKVQKEYALFYKLDIVPI NNNNTTYRLINCNTSTIT 
107 .......................... -gka----ss-wkeeik -----------------i---n---rn--v---dnasttt-y-n----h--r-~-- 
Stu I 
206 ---------------------------n-t-------t-------------i--------------------------------------a-------------- Y 
Mst I 1  
* v3 * * * * 4 *  * * * v4 *--I 
314 IGPGRAIYTTGAIIGDIRQAHCTLNKTQWDNTLRQIAIKLREQFKN KTISFKQSSGGDPEIVMQSFNCGGEFFYCNTTKLFNSTWNDTRLFNSTWNNTIGSNNTE 
312 ------fh---r------k---nisra--n---e--vk------g-n---v-n-----------h----r---------q---n--rlnhtegtkg-d- 
CD4 binding domain 
* "5 * * * * gp41 
r' 
- * - - - 3 - 9 - & - - - % - - - - * - -  
419 GNITLPCRIKQIINE(WQEVGKAMYAPPIRGQIRCSSN1TGLLLTRDGGETNET TEVFRPGGGDMRDNWRSELYKYKWKIEPLGVAPTRAKRRWQREK 
411 -i------------------------g----s---------------tnvtnd------------------------i------i---k---------- 
Fusion domain 
I * * 1 * 
Mst 1; 
* 1 
8 * * * * * * * * * * 
735 DRPDGIEEEGGERDRDRSVRLVDGFLALIWDDLRSLCLFSYHRLRDLLLIAARIVELLGRRGWEVLKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEW 
727 ------------------------------e----------r-----------t--i--h----a-----s-----i---------~--------t---------a 
523 
515 
* * 
8 4 1  QRAFRAILHIPRRVRQGLERALL 
833 ---y------h--i------l-- 
GAVFLGFLGAAGSTMGAASVAL ARQLL~GIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLR~QQLLG IWGCSGKL I CTTTVPWNASWSNKSLDK 
--m--------------v-lt- ------------------------------------------------------------------a------------ed 
FIG. 2. Alignment of the env proteins of HIV-Is,, and HIV-1s,12,A. The translated amino acid sequences of HIV-l,,,,,, gp160 are shown 
on the upper line of each pair of lines, and the sequences of HIV-Is,? are shown on the lower line of each pair. Dashes represent sequence 
homology between the two sequences, and differences are shown with lowercase letters. Hypervariable regions (27) are marked with heavy 
lines, the putative CD4-binding domain (9, 17) is marked by heavy dotted lines, and the gp41 fusion domain (3, 12) is boxed. Restriction 
enzyme sites that were used to generate HIV-lSF2IHIV-l,,,,,, recombinant clones are indicated by arrows. 
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Xho I 
* * * I  * * * 
SF128A nef 1 MGGKWSKRSMGGWSTIRERMKQ AEPAADGVGAASRDLEKHGAITSSNTAATNADCAWLEAQEEEEVG 
* * * I* * * * 
68 FPVRPQVPLRPMTKGALDLSHFLKEKGGLEGLIYSQKRQHHTQGYFPDWQNYTPGPGIRYPLT 
Dupl ica t ion 
FGWLEGLIYSQKRQDILDLWVHHTQGYFPDWQNYTPGPGIRYPLTFGWCFKLVPVEPGQVGWEGENNSL 
FIG. 3.  Alignment of the nef proteins of HIV-I,,, and HIV-l,,,,,,. The translated amino acid sequence of HIV-ls,l,,, nef is shown on 
the upper line of each pair of lines, and the sequence of HIV-I,,, is shown on the lower line of each pair. Dashes represent sequence 
homology, and differences are shown with lowercase letters. The arrow indicates the beginning of the LTR sequence. The heavy line indicates 
a stretch of 45 amino acids representing a direct repeat which is found only in HIV-1sF12nA. The XhoI site that was used to generate 
HIV-1s,2/HIV-1,,12nA recombinant clones is indicated by an arrow. 
Is,, with that of HIV-1,,,,,,. This clone expresses all the 
genes of HIV-Is,, origin except the nef gene, which is from 
HIV-1,,,,,,, and a hybrid env gene. The resulting envelope 
glycoprotein consists of 210 amino acids at the amino 
terminus encoded by the HIV-I,,, sequence and the rest of 
the protein encoded by the HIV-1sF,2,A sequence. A fourth 
clone, RHIV-4, was generated by replacing the HIV-I,,, nef 
XhoI-SstI fragment with that of HIV-l,,l,,A. This clone 
expresses a hybrid nef protein with the first 34 amino acids 
from HIV-Is,, and the rest from HIV-1,,,,,,. A fifth clone, 
RHIV-5, was generated by exchanging a SruI-XhoI fragment 
between the two viruses. The resulting clone expresses a 
hybrid env and a hybrid nef protein. The hybrid envelope 
glycoprotein is identical to the one expressed by RHIV-3, 
with the HIV-I,,, sequence encoding the first 210 amino 
acids and the rest of the protein encoded by HIV-1,,,,,,. 
The hybrid nef protein is also identical to the one expressed 
by RHIV-2, with the first 34 amino acids from HIV-1,,,,,, 
and the rest from HIV-I,,,. Finally, a sixth clone that 
involved the replacement of a 658-bp MstII env fragment 
from HIV-Is,, with the same fragment from HIV-1sF128A, 
was constructed. This region includes the V, and V, do- 
mains of gp120 (27), the CD4-binding domain (9. 17), and the 
fusion domain of gp41 (3, 12). 
Replicative properties of HIV-I,,,,,, and HIV-I,,, recom- 
binant viruses. Plasmid DNA containing the various recom- 
binant clones was transfected into normal human PBMC or 
the human rhabdomyosarcoma RD-4 cell line (19). All clones 
yielded viruses upon transfection, and the progeny HIV-1 
strains produced were then tested for their biologic proper- 
ties by infection of HUT 78 T cells or primary peripheral 
blood macrophages. Infection of PBMC served as a control, 
and all recombinant viruses grew to comparable titers in 
human PBMC within 10 to 12 days postinfection. As ex- 
pected, HIV-I,,, replicated well and produced high-titered 
progeny virus in HUT 78 cells; moreover, as reported 
previously (4, 6), it did not productively infect peripheral 
blood macrophages (Table 1). In contrast, RHIV-1, RHIV-2, 
RHIV-3, and RHIV-5 all infected and replicated well to high 
titers in peripheral blood macrophages, but none of these 
recombinant viruses could infect HUT 78 cells. These clones 
thus reflect the biological properties of the parental virus, 
HIV-1,,,,,,, particularly its macrophage tropism. The re- 
sults indicate that clones that had acquired the HIV-1sF128A 
env gene sequence encoding amino acids 211 onward as well 
as sequences encoding the first 34 amino acids of the nef 
protein produced viruses that were macrophage tropic. The 
only clones that retained the HIV-Is,, T-cell-tropic pheno- 
type were RHIV-4 and RHIV-6. RHIV-4 contains an HIV- 
1sF,2,A fragment coding for only the nef gene, and RHIV-6 
contains the C terminus of gp120 and the fusion domain of 
gp41 from HIV-1,,,,,,. RHIV-6, however, replicates with 
slower kinetics in HUT 78 cells (Table 1). In contrast to 
HIV-I,,,, which replicated rapidly in HUT 78 cells (peak 
RT activity at 12 days postinfection), this recombinant virus 
reached peak RT activity (>500 x lo3 cpmlml) at 20 to 25 
days postinfection. 
DISCUSSION 
Our results demonstrate that no genomic structural differ- 
ences between HIV-1,,,,,, and HIV-Is,, are responsible 
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for the different cellular tropisms displayed by the two 
HIV-1 isolates. The replicative properties of our recombi- 
nant clones indicate that the env gene product from amino 
acid 211 onward and the first 34 amino acids of the nef 
protein contain determinants responsible for T-cell and/or 
macrophage tropism. Much of the variation in env between 
HIV-1sF12,A and HIV-I,,, is located within the hypervari- 
able regions and the CD4-binding domain. Within the first 34 
amino acids of the nef protein, there is a deletion of 4 amino 
acids in HIV-1,F12,A (alanine, glutamic acid, proline, and 
arginine), in addition to  4 amino acid changes (alanine, 
valine, and two arginines). The four amino acid deletions 
occur in a region reported to  be duplicated in other HIV-1 
strains recovered from brain tissue (2; W. O'Brien, Y. 
Koyanagi, J.  Zack, and I. S .  Y. Chen, VIth Int. Conf. AIDS, 
abstr. no. SA1, 1990). Since none of these molecularly 
cloned brain-derived isolates have been found to be biolog- 
ically active, the functional significance of genomic alter- 
ations in this particular region of the nef gene cannot be 
addressed directly. The nef protein has been reported to be 
a negative regulatory protein (1, 24, 28), but its functional 
domains have not been defined. In view of the observation 
that there are no differences in viral production between 
HIV-I,,, and HIV-1,,12,A upon transfection into PBMC, 
we assume that the functions contained within the first 34 
amino acids of the nef protein of HIV-1sF128A and HIV-I,,, 
are similar. We conclude, therefore, that the env gene 
contains the major determinants of T-cell and/or macrophage 
tropism. 
Previous studies with recombinant viruses generated be- 
tween HIV-1 strains with different biologic properties have 
implied a role for the env gene in determining host cell 
tropism (5, 11, 36). However, the exchanged regions contain 
other viral genes, such a s  rat, rev, and vpu. The present 
study was conducted with recombinant viruses by exchang- 
ing only the env-nef region. Our finding that the RHIV-3 and 
RHIV-5 viruses, which contain the V, and V, regions of the 
env gene from HIV-I,,,, still display the macrophage tro- 
pism characteristic of HIV-1sF12,A excludes the possibility 
that these regions play a role in determining this cellular 
tropism. Furthermore, the observation that RHIV-6 is un- 
able to  productively infect primary macrophages indicates 
that the V, and V, domains of gp120, the CD4-binding 
domain, and the fusion domain of gp41 d o  not contain the 
viral determinants of macrophage tropism. The region en- 
coding these domains, however, is necessary for efficient 
infection of the H U T  78 T-cell line. Substitution of this 
region (MstII-MstII fragment) in HIV-I,,, with correspond- 
ing sequences from HIV-1,F12,A resulted in a recombinant 
virus (RHIV-6) that replicates with slower kinetics in H U T  
78 cells (Table 1). This observation could reflect the fact that 
multiple determinants are involved in infection of T-cell 
lines. An earlier report by Cordonnier et al. (7) had indicated 
that a single amino acid substitution at three positions in the 
CD4-binding domain can eliminate the infectivity of the 
U937 monocytic cell line but retain the infectivity of a T-cell 
line. However, our sequence analysis of the CD4 domain, 
especially at those three positions, of HIV-1,,12,A indicated 
that the isoleucine at  position 427, lysine at 528, and glu- 
tamine at  429 are identical to  the corresponding amino acids 
found in HIV-I,,,. Thus, some other portion of the envelope 
gene must be involved in efficient replication of HIV-1. 
In conclusion, our studies with recombinant viruses fur- 
ther demonstrate that a StirI-MstII fragment of the envelope 
glycoprotein gene of HIV-1,,12,A encoding the V, domain 
(30, 31) o r  the MstII-XhoI fragment encoding the C terminus 
of gp41 helps to determine the macrophage tropism of 
HIV-1,,12,A. A SruI-XhoI fragment encoding the envelope 
glycoprotein of HIV-I,,, from amino acid 211 onward 
contains determinants for T-cell tropism. Further fine map- 
ping with recombinants between HIV-1,F12,A and HIV-I,,, 
in the env gene should define the specific domain(s) respon- 
sible for the differential infectivity of macrophage and T-cell 
lines by HIV-1. 
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